Skip to main content

Advertisement

Table 1 Clinical characteristics and outcome of the patients who underwent double stenting

From: Efficacy and safety of chemotherapy after endoscopic double stenting for malignant duodenal and biliary obstructions in patients with advanced pancreatic cancer: a single-institution retrospective analysis

Parameter Number
Age, median (range), years 65 (41–86)
Sex, male, n (%) 33 (66)
Distant metastasis at initical diagnosis, n (%) 33 (66)
Time from initial diagnosis to double stenting (IQR), mo 5.9 (1.1–12.1)
Timing of duodenal and biliary stenoses, n (%)  
 Simultaneous 21 (42)
 Metachronous 29 (58)
Type of duodenal stenosis, n (%)  
 I 20 (40)
 II 21 (42)
 III 9 (18)
GOOSS score, mean ± SD  
 Before DuS 0.9 ± 0.8
 After DuS 2.8 ± 0.4
Biliary drainage methods, n (%)  
 ERCP-BD 35 (70)
 EUS-CDS 12 (24)
 EUS-HGS 3 (6)
Type of biliary stent  
 PS 11 (22)
 MS 39 (78)
Chemotherapy post double stenting, n (%) 21 (42)
Performance status at the double stenting, n (%)  
 0–1 28 (56)
 2–3 22 (44)
Overall survital time (IQR), mo 10.9 (6.0–18.4)
Survival time from double stenting (IQR), mo 2.4 (1.4–5.2)
  1. IQR interquartile range, GOOSS gastric outlet obstruction scoring system
  2. SD standard deviation, DuS duodenal stenting
  3. ERCP-BD endoscopic retrograde cholangiopancreatography-guided biliary drainage
  4. EUS-CDS endoscopic ultrasound-guided choledochoduodenostomy
  5. EUS-HGS endoscopic ultrasound-guided hepaticogastrostomy
  6. PS plastic stent, MS metal stent